Skip to main content

Table 1 Characteristics of pools of sera used as sources of IgGa

From: Identification of new autoantibody specificities directed at proteins involved in the transforming growth factor β pathway in patients with systemic sclerosis

Main clinical characteristics Autoimmunity Number of pools tested b
Healthy blood donors No ANA 1
dcSSc   
   No visceral involvement No ANA 1
   Interstitial lung disease ATA 1
   Scleroderma renal crisis Anti-RNA-pol III Abs 1
lcSSc   
   Pulmonary arterial hypertension ACA 1
   No visceral involvement ACA 1
dcSSc   
   Scleroderma renal crisis ANA with unidentified specificity 1
   Pulmonary arterial hypertension ANA with unidentified specificity 1
   Interstitial lung disease ANA with unidentified specificity 2
   No visceral involvement ANA with unidentified specificity 1
lcSSc   
   Digital ulcers ANA with unidentified specificity 1
   Pulmonary arterial hypertension ANA with unidentified specificity 1
   Interstitial lung disease ANA with unidentified specificity 1
   No visceral involvement ANA with unidentified specificity 2
  1. aAbs: antibodies; ACA: anticentromere antibody; ANA: antinuclear antibody; anti-RNA-pol III Abs: anti-RNA polymerase III antibodies; ATA: antitopoisomerase I antibody; dcSSc: diffuse cutaneous systemic sclerosis; lcSSc: limited cutaneous systemic sclerosis; SSc: systemic sclerosis. bA pool of sera from 12 healthy blood donors was tested as a control. Immunoglobulin G reactivities were tested in pools of three sera from patients with the same phenotype of SSc.